Health Source-linked briefing

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice

Patrick Campbell

Original contributor via Hcplive

| October 30, 2026 | 1 min read | Updated Oct 31, 4:00 AM

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism — Image supplied with the source report: Hcplive.

Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice

Source disclosure

This is a source-linked briefing. Read the original report from Hcplive .

Health us Hcplive